Dept. of Radiology, Xuanwu Hospital, Capital Medical University Beijing:100053 Emeil: 首都 Update of China-ADNI Kuncheng Li.

Slides:

Advertisements

Similar presentations

Corpus Callosum Damage Predicts Disability Progression and Cognitive Dysfunction in Primary-Progressive MS After Five Years.

Advertisements

K OREAN ADNI … WHERE ARE WE NOW Seol-Heui Han, MD, PhD. On behalf of Preparatory Committee for K-ADNI Seol-Heui Han, MD, PhD. On behalf of Preparatory.

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing AUSTRALIAN ADNI. July 2010 UPDATE.

Department of Neurology, Mayo Clinic Arizona

December, NEED FOR VALIDATED BIOMARKERS FOR AD TRIALS Biomarkers useful in Phase 2 to make decisions about Phase 3 (e.g. doses) Biomarkers useful.

TESTING A LEPTIN PRODUCT AS A NOVEL THERAPY FOR ALZHEIMER’S DISEASE

National Alliance for Medical Image Computing Core DBP Dartmouth Data NA-MIC National Alliance for Medical Image Computing

Tony WAEGEMANS, MD UCB Pharma, Belgium. TW/ll/ Washington/MCI 2 MCI as implemented in our study MCI is a very early stage of dementia with as main.

DTI-Based White Matter Fiber Analysis and Visualization Jun Zhang, Ph.D. Laboratory for Computational Medical Imaging & Data Analysis Laboratory for High.

Disclosures/Conflicts Consulting: GE Healthcare Bayer Abbott Elan/Janssen Synarc Genentech Merck.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE April

CSF sulfatide is decreased in individuals with incipient dementia Xianlin Han, PhD, Anne M. Fagan, PhD, Hua Cheng, MS, John C. Morris, MD, Chengjie Xiong,

Mild Cognitive Impairment as a Target for Drug Development Steven H. Ferris, Ph.D. Silberstein Aging and Dementia Research Center New York University School.

MCI Clinical Trial Design FDA Advisory Committee Meeting March 13, 2001 Gaithersburg, MD Michael Grundman, MD, MPH Alzheimer’s Disease Cooperative Study.

Brain Changes in 676 ADNI subjects: Summary of 10 Studies using Tensor Based Morphometry & Automated Hippocampal Maps Paul Thompson and the UCLA ADNI.

TEMPLATE DESIGN © All PET scans were processed to uniform resolution as implemented by ADNI (Joshi, 2009) to minimize.

"THE POTENTIAL OF MULTIMODAL MRI FOR UNDERSTANDING SPORTS CONCUSSION" Victoria Morgan, Ph.D., Manus Donahue, Ph.D., Megan Strother, M.D., Allen Sills,

Dementia in Clinical Practice Mary Ann Forciea MD Clinical Prof of Medicine Division of Geriatric Medicine UPHS Photo: Nat Geographic.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar.

Update Arg-ADNI Gustavo E. Sevlever, Ricardo F. Allegri (*), Silvia Vázquez, Deborah R. Gustafson, Salvador M. Guinjoan, and Arg-ADNI group. Memory and.

COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.

ASNR 2015 Poster# EP-19 Effect of Chemotherapy on Brain Structure and Cognition in Older Women with Breast Cancer: a Brain MRI Study 1 Bihong T. Chen MD.

MRI as a Potential Surrogate Marker in the ADCS MCI Trial

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar WW ADNI Washington, DC July 17, 2015.

Alzheimer’s Disease Neuroimaging Initiative STEERING COMMITTEE Michael W. Weiner.

Medical Image SBIA.UPenn Christos Davatzikos Director, Section of Biomedical Image Analysis Professor, Radiology,

Wei Chen CCNI Journal Club Alzheimer’s disease (AD): imaging & cognition imaging & cognition.

©2012 MFMER | ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar ADNI Steering Committee Meeting Washington, DC April.

NA-MIC National Alliance for Medical Image Computing Mental Illness and Neuroscience Discovery (MIND) Consortium Data Randy L. Gollub,

conflicts of interest to report.

PharmaCog WP5 / E-ADNI. Enrollment and follow-ups Clinical sites Maximum Minimum PATIENTS EXPECTED.

Clinical, cognitive and genetic predictors of conversion from amnestic mild cognitive impairment to Alzheimer’s disease in Chinese older adults (Chu LW,

Structural MRI as a Biomarker of Disease Progression in AD Department of Diagnostic Radiology and MRI Research Lab Presented by Clifford Jack, M.D. at.

Alzheimer’s Disease: Advances and Hope Trey Sunderland, M.D. Chief, Geriatric Psychiatry Branch National Institute of Mental Health Bethesda, Maryland.

Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.

Sven Haller Haller, Nguyen, Rodriguez, Emch, Gold, Bartsch, Lovblad, Giannakopoulos.

MR SPECTROCOPY AND MRI TO MEASURE TREATMENT OF NEURODEGENERATION MICHAEL W. WEINER Professor of Radiology, Medicine, Psychiatry, and Neurology, U.C.S.F.

Advanced brain imaging and neurodegenerative disorders. Dott.ssa Ingrid Inches.

Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of Short- term conversion to AD: Results from ADNI Xuejiao.

INFLUENCE OF FRACTIONAL ANISOTROPY THRESHOLD FOR TRACT BASED DIFFUSION TENSOR ANALYSIS OF UNCINATE FASCICLES IN ALZHEIMER DISEASE Toshiaki Taoka, Toshiaki.

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Plasma Clusterin Concentration With.

DECIDE: "Scientific and Clinical Perspectives“: Claudio Babiloni (UNIFG) and Giovanni Frisoni (IRCCS Brescia)

Update of China-ADNI Kuncheng Li, MD. PhD.

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Metabolic Syndrome and Progression of Mild Cognitive Impairment

Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI 3)

Rosa Maria Moresco University of Milan Bicocca

Manuela Tondelli, Gordon K. Wilcock, Paolo Nichelli, Celeste A

Update of China-ADNI Kuncheng Li, MD. PhD.

Mohammad Kassir, PGY4, R3 September 15th, 2016

Whole brain white matter changes revealed by multiple diffusion metrics in multiple sclerosis: A TBSS study Yaou Liu, Yunyun Duan, Yong He, Chunshui.

Paul Aisen Ron Petersen Michael Donohue Jennifer Salazar

COMBINATION OF CSF PROTEIN BIOMARKERS AND BDNF, IL10 AND IL6 GENOTYPES IN EARLY DIAGNOSIS OF ALZHEIMER’S DISEASE Mirjana Babić Leko1, Matea Nikolac Perković2,

Use of Amyloid PET Scan in Early Diagnosis of Alzheimer’s Disease in a Secondary Care Memory Clinic Niki Schoonenboom, MD PhD1, Mohammed Akarriou, MD2;

Evaluation of Hyperbaric Oxygen Treatment in Acute Traumatic Spinal Cord Injury in Rats Using Diffusion Tensor Imaging Sun Wenzhi 1 ;Li Zhuo 2 ;Lu Shibao.

Table 2. Data Sharing for (Reporting Period)

ADI Disease International 7-10 March, 2012

ADNI3 Clinical core Paul Aisen Ron Petersen Mike Donohue

José L Molinuevo, Craig Ritchie, Miia Kivipelto

Update of China-ADNI Kuncheng Li, MD. PhD.

ADNI Clinical Core Paul Aisen Ron Petersen Michael Donohue

Ron Petersen & Paul Aisen

Update of China-ADNI Kuncheng Li, MD. PhD.

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W

Boston Naming Test predicts deterioration of cerebrospinal fluid biomarkers in pre-symptomatic Alzheimer’s disease Charleen Wilder, MA, Kristina Moncrieffe,

Biomarker Modeling of Alzheimer’s Disease

Tharick A. Pascoal, Sulantha Mathotaarachchi, Monica Shin, Andrea L

Background of PI Name: Wen-Yih Isaac Tseng, MD, PhD

Figure 1 NMF in ADD patients and classification of prodromal Alzheimer’s disease participants. Grey matter ... Figure 1 NMF in ADD patients and classification.

Presentation transcript:

Dept. of Radiology, Xuanwu Hospital, Capital Medical University Beijing: Emeil: 首都 Update of China-ADNI Kuncheng Li. M.D., Ph.D.

Outline  General information of China-ADNI  Progress of the main cores

ADI-ChinaScientist advisory board Administration committee PI: Prof. Kuncheng Li, CMU CO-PI: Prof. Jun Wang, BJU CO-PI: Prof. Hongzheng Wang, BUMC Clinical core Liyan Qiao MRI core Kuncheng Li PET core Fang Li Biomarker and Genetics Core Jun Wang/Yan Zhang Biostatistics and Informatics core Li Wang DATA Post process Yong Fang Patholoy core Cuidi Wang

Research plan ： subjects subjects (80 sites) NormalEarly MCILate MCIMild AD

 Neuropsychological battery  Biomarkers: Blood: Apo E polymorphism, Amyloid 40/42, tau CSF: Amyloid 40/42, tau  MRI: Multi-modality  PET: FDG-PET and amyloid Imaging of PET (later this year) Research plan ： examinations

 6 cities joined in this study,  distributed in the northern, eastern, central and southwestern area of china mainland.

Enrolled subjects  44 new subjects enrolled in the year past, now we have totally 85 cases collected. NormalEarly MCILate MCIMild AD

Outline  General information of China-ADNI  Progress of the main cores

 Screen : MMSE, LM-I, LM-II, GDS, CDR  Baseline : ADAs-Cog ， ECOG ， CWRT ， MoCA, BNT, Rey AVLT(30’ Delay), Category Fluency(animal),Trial A& B,NPI, FAQ  6 month later : ADAs-Cog ， ECOG, MMSE, CDR, MoCA, BNT, Rey AVLT(30’ Delay), Category Fluency(animal),Trial A& B,NPI, FAQ  12 month later : ADAs-Cog ， ECOG, MMSE, LM-I, LM-II, GDS, CDR, MoCA, BNT, Rey AVLT(30’ Delay), Category Fluency(animal),Trial A& B,NPI, FAQ  24 month later: ADAs-Cog ， ECOG, MMSE, LM-I, LM-II, GDS, CDR, MoCA, BNT, Rey AVLT(30’ Delay), Category Fluency(animal),Trial A& B,NPI, FAQ  36 month later: ADAs-Cog ， ECOG, MMSE, LM-I, LM-II, GDS, CDR, MoCA, BNT, Rey AVLT(30’ Delay), Category Fluency(animal),Trial A& B,NPI, FAQ Neuropsychological battery

Changes of MMSE score in different groups

Changes of MoCA score in different groups

Biomarker study DiagnosisAPOE typeAβ42 (pg/ml)Aβ40 (pg/ml) NCε2/349/ NCε3/335/ NCε2/236/ NCε3/3 NCε2/3/ NCε3/4/91.07 NCε3/3/ NCε3/3/8.11 MCIε2/365/ MCIε3/3// MCIε2/2// MCIε3/3/ MCIε4/4/ EMCIε3/3/82.72 EMCIε2/3// EMCIε3/3

DiagnosisAPOE typeAβ42 (pg/ml)Aβ40 (pg/ml) EMCIε3/3/ EMCIε2/3/96.53 EMCIε3/3/38 EMCIε3/3/108 LMCIε3/3// LMCIε4/4/ LMCIε3/381/ ADε3/348/ ADε2/339/ ADε3/362/ ADε3/3/ ADε3/3/91.21 /ε3/3/24 Biomarker study

MRI Study  Standard protocol for MRI acquisition  Quality control among different sites  Improve the post-processing methods

 3D T1 volume  Diffusion tensor imaging  Resting state fMRI  Arterial spin labelling  Susceptibility weighted imaging MRI Protocol

A individual-level inline morphometry analysis Hippocampus and left temporal cortex are significant in distinguishing AD or AD+MCI from normal elderly, while the discrimination of MCI seems difficult A new brain template based on 2020 normal Han people

decreased FA value A TBSS (tract Based Statial Statistics) study demonstrated that MD value was increased and FA value was degreased, in mild AD, however, MD is more significant than FA value in detecting the mild AD Increased MD value

PET Study  18 F FDG-PET baseline examination (34 cases)  Amyloid-PET-MRI will be performed later this year NC MCI AD

19 Many thanks to the support from WW-ADNI ！

Thank you!